October 29, 2018 06:38 AM EDT

On a roll, Dicerna notches $100M upfront as Eli Lilly eyes RNAi applications in neurodegeneration, pain

Amber Tong

Just days after selling co-development rights to two of its preclinical RNAi therapies to Alexion for a cool $22 million, Dicerna has scored another …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

On a roll, Dicerna notches $100M upfront as Eli Lilly eyes RNAi applications in neurodegeneration, pain

Amber Tong

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Biotech seed rounds sink to lowest level in years as industry slump drags on

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Trump pledges his support for a change to the IRA long sought by drugmakers

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

On a roll, Dicer­na notch­es $100M up­front as Eli Lil­ly eyes RNAi ap­pli­ca­tions in neu­rode­gen­er­a­tion, pain

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

On a roll, Dicerna notches $100M upfront as Eli Lilly eyes RNAi applications in neurodegeneration, pain